AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30471345 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg ICG
Number of subjects: 45
Study 30471345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg ICG
Number of subjects: 45
Study 30471555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (NC) containing red yeast rice and berberine
Number of subjects: 30
Study 30471555 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (noNC)
Number of subjects: 30
Study 30471649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (E7080)
Number of subjects: 0
Study 30471652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib-cyclophosphamide-dexamethasone (ICd) followed by ixazomib maintenance; 4.0 mg of ixazomib, 300 mg (Arm A) or 400 mg (Arm B)
Number of subjects: 70
Study 30471652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib maintenance
Number of subjects: 70
Study 30471965 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over ipsilesional primary motor cortex
Number of subjects: 7
Study 30471965 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over contralesional primary motor cortex
Number of subjects: 7
Study 30472259 — intervention group
Group type: EXPERIMENTAL
Intervention: High PALB2 mRNA expression
Number of subjects: 177
Study 30472317 — intervention group
Group type: EXPERIMENTAL
Intervention: High pretherapy psychoneurological symptoms (n = 51; 16%)
Number of subjects: 666
Study 30472317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pretherapy psychoneurological symptoms (n = 268; 84%)
Number of subjects: 666
Study 30472317 — intervention group
Group type: COMPARATOR
Intervention: Matched noncancer controls (n = 347)
Number of subjects: 666
Study 30472553 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol) 100,000 IU bolus dose followed by 20,000 IU per week
Number of subjects: 422
Study 30472553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 30472651 — intervention group
Group type: EXPERIMENTAL
Intervention: ld-IL2 (1 million IU/day for 5 days, followed by fortnightly injections for 6 months)
Number of subjects: 46
Study 30472660 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous EEG monitoring with antiepileptic drugs (AEDs)
Number of subjects: 214
Study 30472660 — intervention group
Group type: COMPARATOR
Intervention: Continuous EEG monitoring without antiepileptic drugs (AEDs)
Number of subjects: 214
Study 30472660 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous EEG monitoring
Number of subjects: 214
Study 30472975 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Purchase Index (HPI)
Number of subjects: 112
Study 30473706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin or oxaliplatin
Number of subjects: 71
Study 30473794 — intervention group
Group type: EXPERIMENTAL
Intervention: AT gamma (36 IU/kg/day)
Number of subjects: 222
Study 30473794 — intervention group
Group type: COMPARATOR
Intervention: pAT (30 IU/kg/day)
Number of subjects: 222
Study 30474567 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine (10, 30, or 60 mg/day)
Number of subjects: 2506
Study 30474567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2506
Study 30474818 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp (insulin degludec/insulin aspart) administered twice daily (BID)
Number of subjects: 2
Study 30474818 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 administered twice daily (BID)
Number of subjects: 2
Study 30475172 — intervention group
Group type: EXPERIMENTAL
Intervention: FES rowing exercise program
Number of subjects: 0
Study 30475172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30475331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 26
Study 30475331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning with PLR+
Number of subjects: 26
Study 30475331 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning with PLR-
Number of subjects: 26
Study 30475947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years
Number of subjects: 84
Study 30475950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years
Number of subjects: 170
Study 30475958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal FADS genotypes
Number of subjects: 390
Study 30475970 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinyl esters (REs)
Number of subjects: 27
Study 30475970 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum VA as REs >7.5%
Number of subjects: 27
Study 30475970 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol sensitivity
Number of subjects: 27
Study 30475970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic α-retinol
Number of subjects: 27
Study 30475970 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic indicators of toxicity
Number of subjects: 27
Study 30475972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 351
Study 30475972 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake by 2 servings/wk
Number of subjects: 351
Study 30475973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST) ≥8 h/d
Number of subjects: 71
Study 30475973 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) ≥30 min/d
Number of subjects: 71
Study 30475973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 71
Study 30475973 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 71
Study 30475973 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in adiposity over 2 years
Number of subjects: 71
Study 30476157 — intervention group
Group type: COMPARATOR
Intervention: 1 can of tomato-soy juice per day
Number of subjects: 0
Study 30476157 — intervention group
Group type: COMPARATOR
Intervention: 2 cans of tomato-soy juice per day
Number of subjects: 0
Study 30476179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ethinyl estradiol and desogestrel pill (PILL)
Number of subjects: 73
Study 30476179 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β-estradiol transdermal patch (PATCH)
Number of subjects: 73
Study 30476179 — intervention group
Group type: COMPARATOR
Intervention: No estrogen/progesterone (NONE)
Number of subjects: 73
Study 30476655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical pain, temporal summation of pain (TSP), negative affect, behavioral coping style
Number of subjects: 234
Study 30476655 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, education, axillary dissection, reconstruction, negative affect, depression scores
Number of subjects: 234
Study 30476655 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, education, axillary dissection, reconstruction, TSP, reinterpreting coping style
Number of subjects: 234
Study 30476723 — intervention group
Group type: EXPERIMENTAL
Intervention: Apabetalone
Number of subjects: 0
Study 30476968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (500 mg/m2) plus irinotecan (180 mg/m2) biweekly
Number of subjects: 28
Study 30477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including dietary changes and physical activity recommendations
Number of subjects: 1000
Study 30477037 — intervention group
Group type: COMPARATOR
Intervention: Standard care without specific lifestyle intervention
Number of subjects: 1000
Study 30477317 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department bypass
Number of subjects: 13219
Study 30477436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessed by the Montreal Cognitive Assessment, Trail making A and B, ten-word immediate and delayed recall test, Controlled Oral Word Association, Global Deterioration Scale, Ascertain Dementia 8 item informant questionnaire.
Number of subjects: 816
Study 30477436 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers including magnetic resonance imaging, routine blood samples, and bio-banking.
Number of subjects: 816
Study 30477436 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessments including characteristics of the stroke, comorbidity, delirium, frailty, cognitive and physical function tests, sensor-based activity monitoring, and adherence to secondary prophylaxis.
Number of subjects: 816
Study 30477455 — intervention group
Group type: EXPERIMENTAL
Intervention: PBI-4050 at a total daily oral dose of 800 mg for an initial 24 weeks with continuation for an additional 36 or 48 weeks
Number of subjects: 18
Study 30477455 — intervention group
Group type: EXPERIMENTAL
Intervention: PBI-4050
Number of subjects: 18
Study 30477513 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation from scratch
Number of subjects: 12851
Study 30477513 — intervention group
Group type: COMPARATOR
Intervention: Food preparation behaviors
Number of subjects: 12851
Study 30477518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep (10% increase in mean sleep time, 65 min)
Number of subjects: 380
Study 30477518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior (10% increase, 47 min)
Number of subjects: 380
Study 30477518 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Physical Activity (LPA) (10% increase, 29 min)
Number of subjects: 380
Study 30477518 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA) at 2 and 3.5 years
Number of subjects: 380
Study 30477529 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS 2 (varying high-frequency 80-100 Hz, 350 μs)
Number of subjects: 63
Study 30477529 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS 1 (constant frequency 100-Hz, 100-μs)
Number of subjects: 63
Study 30477529 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TENS unit without electrical stimulation)
Number of subjects: 63
Study 30477541 — intervention group
Group type: EXPERIMENTAL
Intervention: Best PEEP (calculated with a PEEP test) before and after CPB and CPAP (equal to the best PEEP) during CPB
Number of subjects: 0
Study 30477541 — intervention group
Group type: COMPARATOR
Intervention: Zero PEEP before and after CPB and no ventilation (patient disconnected from the circuit) during CPB
Number of subjects: 0
Study 30477544 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg IM ketamine
Number of subjects: 184
Study 30477544 — intervention group
Group type: COMPARATOR
Intervention: 5 mg IM midazolam and 5 mg IM haloperidol
Number of subjects: 184
Study 30477550 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine administration
Number of subjects: 4
Study 30477550 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine exposure in fibroblasts
Number of subjects: 4
Study 30477550 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal shift analysis of recombinant p.Q188R GALT protein with arginine
Number of subjects: 4
Study 30477572 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal preadipocytes
Number of subjects: 126
Study 30477572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteofemoral preadipocytes
Number of subjects: 126
Study 30477572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of ATAC-seq and RNA-seq
Number of subjects: 126
Study 30477678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training in water
Number of subjects: 36
Study 30477678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training on land
Number of subjects: 36
Study 30477808 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 10000
Study 30477808 — intervention group
Group type: COMPARATOR
Intervention: Standard tubal ligation (TL)
Number of subjects: 10000
Study 30477895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) infants (n=63)
Number of subjects: 85
Study 30477895 — intervention group
Group type: COMPARATOR
Intervention: Non-CF infants (control group, n=22)
Number of subjects: 85
Study 30477928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bentley BeGrow™ stent system
Number of subjects: 2
Study 30478024 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Number of subjects: 0
Study 30478024 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 30478130 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of clinically important improvement on two out of three measures: Fugl-Meyer Upper Limb (change ≥10 points), Motor Assessment Scale item 6 (change ≥1 point), Rating of Everyday Arm-use in the Community and Home (change ≥1 point).
Number of subjects: 78
Study 30478130 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain biomarkers of structure and function indexed using transcranial magnetic stimulation and MRI.
Number of subjects: 78
Study 30478130 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke survivor's perception of recovery and real-world arm use via accelerometry.
Number of subjects: 78
Study 30478130 — intervention group
Group type: EXPERIMENTAL
Intervention: Trajectory of recovery across clinical, a priori defined biomarkers and exploratory variables related to functional connectivity.
Number of subjects: 78
Study 30478168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous colistimethate sodium (CMS) with a loading dose of 9 million international units (MU) followed by a maintenance dose of 3 MU every 8 hours.
Number of subjects: 10
Study 30478168 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium (CMS)
Number of subjects: 10
Study 30478168 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin
Number of subjects: 10
Study 30478190 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82) 400 mg once daily (q.d.)
Number of subjects: 52
Study 30478190 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82) 20-800 mg (various dosing regimens)
Number of subjects: 52
Study 30478190 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib (X-82)
Number of subjects: 52
Study 30478423 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 blockade
Number of subjects: 0
Study 30478983 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chamber ICDs
Number of subjects: 1862
Study 30478983 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber ICDs
Number of subjects: 1862
Study 30478983 — intervention group
Group type: EXPERIMENTAL
Intervention: All device subgroups
Number of subjects: 1862
Study 30479195 — intervention group
Group type: COMPARATOR
Intervention: Niraparib
Number of subjects: 0
Study 30479195 — intervention group
Group type: COMPARATOR
Intervention: Olaparib
Number of subjects: 0
Study 30479195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30479642 — intervention group
Group type: EXPERIMENTAL
Intervention: NUT A (LopiGLIK®: berberine, red yeast rice powder, and leaf extract)
Number of subjects: 28
Study 30479648 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum levels of TMAO in PLC patients
Number of subjects: 1342
Study 30479648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum levels of choline
Number of subjects: 1342
Study 30479648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1342
Study 30480082 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol, glucose, and malate (RGM) - 15 mL per dose (5 g dextrose, 5 g malate, 5 mg resveratrol) twice a day for 1 year
Number of subjects: 39
Study 30480082 — intervention group
Group type: COMPARATOR
Intervention: Placebo - matching placebo ingested with an 8 oz glass of commercial unsweetened grape juice twice a day for 1 year
Number of subjects: 39
Study 30480163 — intervention group
Group type: EXPERIMENTAL
Intervention: FV vouchers for low-income households
Number of subjects: 95
Study 30480163 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of non-participants
Number of subjects: 95
Study 30480323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab administered by intravenous infusion (dosage regimen not specified)
Number of subjects: 0
Study 30480323 — intervention group
Group type: COMPARATOR
Intervention: Placebo or intravenous glucocorticoid therapy
Number of subjects: 0
Study 30480489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Dose CT (RD)
Number of subjects: 52
Study 30480489 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose CT (SD)
Number of subjects: 52
Study 30480489 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (ASIR-V)
Number of subjects: 52
Study 30480549 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose radiotherapy (SDRT) at a dosage of 24 Gy
Number of subjects: 0
Study 30480549 — intervention group
Group type: COMPARATOR
Intervention: 3×9 Gy fractionated radiotherapy
Number of subjects: 0
Study 30481287 — intervention group
Group type: EXPERIMENTAL
Intervention: RT50 (50 Gray radiotherapy)
Number of subjects: 62
Study 30481287 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT45 (45 Gray chemoradiotherapy)
Number of subjects: 62
Study 30481287 — intervention group
Group type: COMPARATOR
Intervention: CRT75 (75 Gray chemoradiotherapy)
Number of subjects: 62
Study 30481287 — intervention group
Group type: EXPERIMENTAL
Intervention: RT50
Number of subjects: 62
Study 30481287 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT45
Number of subjects: 62
Study 30481287 — intervention group
Group type: COMPARATOR
Intervention: CRT75
Number of subjects: 62
Study 30481480 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction in professional athletes
Number of subjects: 1809
Study 30481480 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction in recreational athletes
Number of subjects: 1809
Study 30481480 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for septic arthritis
Number of subjects: 1809
Study 30481480 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after ACL reconstruction
Number of subjects: 1809
Study 30482134 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including offers of deceased organ donation from specially trained designated requesters using a structured conversation separate to end-of-life discussions.
Number of subjects: 164
Study 30482134 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention control group
Number of subjects: 164
Study 30482159 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided discussions (periodic reflections) conducted via telephone for 30-60 minutes at monthly or bi-monthly intervals.
Number of subjects: 0
Study 30482159 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic reflections as a method of documenting implementation phenomena.
Number of subjects: 0
Study 30482187 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes/possible diabetes
Number of subjects: 63450
Study 30484084 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 341
Study 30484408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) subjects
Number of subjects: 400
Study 30484408 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with conversion risk
Number of subjects: 400
Study 30484408 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk classification using rt. HV and neuropsychological tests
Number of subjects: 400
Study 30484934 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning strategies for mesenchymal stem cells (MSCs)
Number of subjects: 0
Study 30484934 — intervention group
Group type: COMPARATOR
Intervention: Mesenchymal stem cells (MSCs)
Number of subjects: 0
Study 30485854 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg taken as needed with psychosocial interventions
Number of subjects: 378
Study 30485854 — intervention group
Group type: COMPARATOR
Intervention: Simple psychosocial intervention (Cohort-B)
Number of subjects: 378
Study 30486767 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cell-free DNA levels above the median (9800 alleles/mL)
Number of subjects: 97
Study 30486767 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cell-free DNA levels below the median (9800 alleles/mL)
Number of subjects: 97
Study 30486767 — intervention group
Group type: COMPARATOR
Intervention: Upper normal limit from a previously analyzed normal control group
Number of subjects: 97
Study 30486767 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum carcinoembryonic antigen and C-reactive protein levels
Number of subjects: 97
Study 30486767 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein combined
Number of subjects: 97
Study 30486836 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulary restriction at the organizational level
Number of subjects: 0
Study 30486836 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician/patient informed decision-making
Number of subjects: 0
Study 30486865 — intervention group
Group type: EXPERIMENTAL
Intervention: Grain consumption
Number of subjects: 900
Study 30486865 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus fruit consumption
Number of subjects: 900
Study 30486889 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular complications
Number of subjects: 15992
Study 30486889 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrovascular complications
Number of subjects: 15992
Study 30487072 — intervention group
Group type: EXPERIMENTAL
Intervention: In-lab insertion (CATH lab, EP lab, or operating room)
Number of subjects: 1222
Study 30487072 — intervention group
Group type: COMPARATOR
Intervention: Out-of-lab insertion
Number of subjects: 1222
Study 30487072 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICM procedure
Number of subjects: 1222
Study 30487116 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based intervention delivered through Facebook groups, consisting of five 1-week sessions.
Number of subjects: 41
Study 30487116 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media-based intervention
Number of subjects: 41
Study 30487142 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for iron deficiency using serum ferritin at 15 or 18 months
Number of subjects: 0
Study 30487142 — intervention group
Group type: COMPARATOR
Intervention: Concurrent measurement of CRP
Number of subjects: 0